A 15-day-old preterm neonate (born at 28 weeks gestation, now on mechanical ventilation) develops late-onset sepsis (LOS) with fever and clinical deterioration. Gram-positive cocci in clusters are isolated from blood culture. What is the drug of choice for treatment of this suspected *Staphylococcus aureus* infection?

Explanation

## Late-Onset Neonatal Sepsis and *Staphylococcus aureus* ### Epidemiology of LOS in NICU **Key Point:** Late-onset sepsis (LOS, ≥72 hours to 28 days of age) in hospitalized neonates is predominantly caused by nosocomial pathogens: *Staphylococcus aureus* (including MRSA), coagulase-negative staphylococci, *Candida*, and gram-negative organisms. The risk of methicillin-resistant *S. aureus* (MRSA) in NICU settings is substantial and varies by institution. ### Why Vancomycin is First-Line for Suspected *S. aureus* in Neonatal LOS | Feature | Vancomycin | Nafcillin/Oxacillin | Cephalothin | |---------|-----------|-------------------|-------------| | **MRSA coverage** | ✓ Excellent | ✗ No (β-lactamase resistant but not MRSA-active) | ✗ No | | **MSSA coverage** | ✓ Yes | ✓ Yes (superior PK) | ✓ Yes | | **Empiric use in NICU** | ✓ Standard | ✗ Only if MSSA confirmed | ✗ Outdated | | **Neonatal dosing** | 10–15 mg/kg/dose IV q8–12h | 25 mg/kg/dose IV q6h | Not recommended | | **Penetration to infected sites** | Good (bone, lung, CNS) | Excellent | Moderate | **High-Yield:** In the NICU setting, the prevalence of MRSA is unpredictable and institution-dependent. Vancomycin is empirically chosen for suspected *S. aureus* because it covers both methicillin-sensitive (MSSA) and methicillin-resistant strains. Once susceptibilities are available and MSSA is confirmed, nafcillin (superior neonatal PK) may be substituted. **Clinical Pearl:** Gram-positive cocci in clusters strongly suggests *Staphylococcus* species. In a hospitalized preterm neonate with LOS, assume MRSA until proven otherwise. Vancomycin is the safest empiric choice. **Mnemonic:** **MRSA in NICU = Vancomycin Vigilance** — Always use vancomycin for empiric coverage of *S. aureus* in late-onset neonatal sepsis until culture susceptibilities are known. ### Neonatal Dosing Considerations - **Vancomycin:** 10–15 mg/kg/dose IV every 8–12 hours (adjust for renal function and age). - **Nafcillin:** 25 mg/kg/dose IV every 6 hours (superior CNS penetration and neonatal clearance compared to oxacillin). - **Cephalothin:** Rarely used in neonates; poor MRSA coverage and inferior to vancomycin. [cite:Nelson Textbook of Pediatrics 21e Ch 128; AAP Red Book 2021]